Tonix Pharmaceuticals Holding Corp
Statements
Income Statement
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19,388.55 | 36,312.10 | 34,568.25 | 594.55 | 499.69 | 1.14 | 0.41 | 0.27 | 0.37 | 0.63 | 0.50 | 0.81 | 1.75 | |
| 11,538.84 | 22,744.31 | 23,119.78 | 906.64 | 275.34 | 0.52 | 0.16 | 0.45 | 0.15 | 0.18 | 0.16 | 0.04 | 0.35 | |
| 7,849.71 | 13,567.79 | 11,448.47 | -312.09 | 224.35 | 0.62 | 0.25 | -0.17 | 0.22 | 0.45 | 0.35 | 0.77 | 1.40 | |
| 102,313.60 | 164,504.66 | 179,150.42 | 2,611.39 | 1,613.82 | 3.67 | 1.25 | 1.48 | 1.04 | 1.99 | 1.33 | 1.17 | 3.84 | |
| 42,344.71 | 111,665.23 | 129,665.74 | 2,020.07 | 1,364.68 | 1.50 | 1.70 | 2.21 | 2.88 | 3.09 | 2.09 | 2.16 | 7.01 | |
| 144,658.31 | 298,914.19 | 308,816.16 | 4,631.46 | 2,978.50 | 10.55 | 2.96 | 3.69 | 3.92 | 6.12 | 3.38 | 3.33 | 11.35 | |
| -136,808.59 | -262,602.09 | -297,367.69 | -4,943.55 | -2,754.15 | -9.93 | -2.71 | -3.86 | -3.71 | -5.67 | -3.03 | -2.56 | -9.94 | |
| – | – | 24,930.36 | – | 53.30 | – | – | – | 0.00 | 0.01 | – | – | – | |
| -135,972.59 | -262,534.83 | -208,064.07 | -21,212.10 | -2,516.70 | -9.77 | -2.84 | -3.86 | -3.59 | -5.51 | -2.93 | -2.44 | -9.60 | |
| -5,910.37 | – | -16,852.37 | – | – | 0.02 | – | – | – | – | – | – | – | |
| -135,972.59 | -262,534.83 | -208,064.07 | -21,212.10 | -2,516.70 | -9.77 | -2.84 | -3.86 | -3.59 | -5.51 | -2.93 | -2.44 | -9.60 | |
| -131,219.01 | – | -191,211.70 | -20,887.63 | -2,426.40 | -9.55 | -2.76 | -3.79 | -3.54 | -5.45 | -2.89 | -2.40 | -9.47 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.